Rode Kruis Ziekenhuis B.V.

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Obesity3 trials
• Atrial fibrillation2 trials
• Stroke2 trials
• Chronic lymphocytic leukaemia1 trial
• Colorectal cancer1 trial
• Coronary artery disease1 trial
• Heart failure1 trial
• High blood pressure1 trial
• Multiple myeloma1 trial
• Prostate cancer1 trial
• Triple-negative breast cancer1 trial
• Type 2 diabetes1 trial

Phase

• Phase 311 trials
• Phase 41 trial

Status

• Recruiting10 trials
• Completed2 trials

Lead sponsor

• Novo Nordisk A/S2 trials
• Amgen1 trial
• Bayer AG1 trial
• Boehringer Ingelheim1 trial
• Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)1 trial
• and 6 more

Running trials

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment

  2025-524283-38-00· Phase 3· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source

• Recruiting

  ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

  NCT06716021· Phase 3· Milestone Pharmaceuticals Inc.· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

  NCT07486687· Phase 3· The Netherlands Cancer Institute· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Semaglutide 2.4mg for low responders after bariatric surgery

  2022-502164-20-01· Phase 4· Stichting Zuyderland Medisch Centrum· Source

• Recruiting

  DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

  NCT06275958· Phase 3· Leiden University Medical Center· Source

• Recruiting

  FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

  NCT06187441· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume castration-sensitive prostate cancer: a randomized Nationwide Study

  2023-506698-36-00· Phase 3· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Atrial fibrillation1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Multiple myeloma1 recruiting
• Prostate cancer1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source